Concourse Financial Group Securities, Inc. Moon Lake Immunotherapeutics Transaction History

Concourse Financial Group Securities, Inc.

$1.52 Billion
Q1 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$43.78 - $63.86 $0 - $0	0 New	0 $0
Q4 2023 Feb 07, 2024	BUY	$36.35 - $63.02 $0 - $0	0 New	0 $0
Q3 2023 Oct 30, 2023	BUY	$48.35 - $61.26 $0 - $0	0 New	0 $0
Q3 2023 Oct 25, 2023	BUY	$48.35 - $61.26 $0 - $0	0 New	0 $0
Q2 2023 Aug 10, 2023	BUY	$19.01 - $51.79 $0 - $0	0 New	0 $0

Q1 2023 May 15, 2023	BUY	$11.03 - $23.7 $0 - $0	0 New	0 $0
Q4 2022 Jan 30, 2023	BUY	$7.56 - $10.5 $0 - $0	0 New	0 $0
Q3 2022 Nov 15, 2022	BUY	$5.25 - $9.27 $0 - $0	0 New	0 $0
Q2 2022 Aug 09, 2022	BUY	$4.69 - $13.25 $0 - $0	0 New	0 $0

Others Institutions Holding MLTX

# of Institutions

135

Shares Held

56M

Call Options Held

379K

Put Options Held

402K

Bvf Inc San Francisco, CA

21.8M
Shares

$873 Million
32.73% of portfolio
Cormorant Asset Management, LP Boston, MA

8.49M
Shares

$341 Million
24.56% of portfolio
Avoro Capital Advisors LLC New York, NY

2.58M
Shares

$104 Million
1.56% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

2.31M
Shares

$92.7 Million
0.02% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

2.28M
Shares

$91.7 Million
0.23% of portfolio

View Full List

About MoonLake Immunotherapeutics

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.48B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

More about MLTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account